U.S. markets closed

GenSight Biologics S.A. (GSGTF)

OTC Markets OTCPK - OTC Markets OTCPK Precio retrasado. Moneda en USD.
Añadir a la lista de seguimiento
0.4500-0.0200 (-4.26%)
Al cierre: 12:14PM EDT

GenSight Biologics S.A.

74, rue du Faubourg Saint-Antoine
Paris 75012
France
33 1 76 21 72 20
https://www.gensight-biologics.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo16

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Ms. Laurence RodriguezCEO & DirectorN/DN/D1968
Dr. Jose-Alain Sahel M.D., Ph.D.Scientific Founder, Vice Chairman of Scientific Advisory Board & Board ObserverN/DN/DN/D
Prof. Botond Roska M.D., Ph.D.Scientific Founder & Chairman of Scientific Advisory BoardN/DN/DN/D
Dr. Luk H. Vandenberghe M.D., Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/DN/DN/D
Dr. Serge Picaud Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/DN/DN/D
Dr. Constance L. Cepko Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/DN/DN/D
Mr. Ivan TortetChief Financial OfficerN/DN/D1966
Mr. Scott JeffersChief Technical OfficerN/DN/DN/D
Dr. Barrett Katz CMO, M.B.A., M.D.ConsultantN/DN/D1951
Dr. Magali Taiël M.D.Chief Medical OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

Gestión corporativa

La calificación ISS Governance QuickScore de GenSight Biologics S.A. a partir del 1 de junio de 2024 es 10. Las puntuaciones principales son Auditoría: 10; Junta: 10; Derechos del accionista: 4; Compensación: 10.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.